Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the ...
Pharmaceutical Technology on MSN13h
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKAbrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to prevent ...
Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...
Indoor air quality is a silent public health crisis, harbouring pathogens that contribute to billions of illnesses annually ...
Planet Classroom, the global youth-driven media network, unveils an extraordinary selection of films for April 2025, featuring trailblazing innovations in AI, climate action, classical music, and ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...
An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback